First Trust Advisors’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $90M | Buy |
4,135,788
+2,143,211
| +108% | +$41.5M | 0.06% | 376 |
|
|
2025
Q4 | $42.9M | Buy |
1,992,577
+52,796
| +3% | +$1.11M | 0.03% | 624 |
|
|
2025
Q3 | $37.4M | Buy |
1,939,781
+1,312,220
| +209% | +$23.4M | 0.03% | 697 |
|
|
2025
Q2 | $10.7M | Buy |
627,561
+233,391
| +59% | +$9.96M | 0.01% | 1064 |
|
|
2025
Q1 | $25.2M | Buy |
394,170
+82,385
| +26% | +$8.67M | 0.02% | 791 |
|
|
2024
Q4 | $37.9M | Sell |
311,785
-153,131
| -33% | -$18.8M | 0.03% | 639 |
|
|
2024
Q3 | $58.1M | Buy |
464,916
+363,000
| +356% | +$50.2M | 0.06% | 446 |
|
|
2024
Q2 | $16.1M | Buy |
+101,916
| New | +$13.1M | 0.02% | 857 |
|
|
2024
Q1 | – | Sell |
-432,350
| Closed | -$41.7M | – | 2407 |
|
|
2023
Q4 | $41.7M | Buy |
432,350
+1,376
| +0.3% | +$132K | 0.05% | 474 |
|
|
2023
Q3 | $52.2M | Sell |
430,974
-173,362
| -29% | -$19.6M | 0.06% | 406 |
|
|
2023
Q2 | $69.2M | Sell |
604,336
-85,276
| -12% | -$11M | 0.08% | 371 |
|
|
2023
Q1 | $95M | Sell |
689,612
-18,334
| -3% | -$2.38M | 0.11% | 245 |
|
|
2022
Q4 | $91.7M | Sell |
707,946
-209,296
| -23% | -$24.3M | 0.11% | 260 |
|
|
2022
Q3 | $101M | Buy |
917,242
+226,947
| +33% | +$22.9M | 0.13% | 190 |
|
|
2022
Q2 | $51.7M | Sell |
690,295
-169,453
| -20% | -$12.5M | 0.06% | 443 |
|
|
2022
Q1 | $67.2M | Sell |
859,748
-39,308
| -4% | -$3.01M | 0.07% | 404 |
|
|
2021
Q4 | $81M | Sell |
899,056
-30,152
| -3% | -$2.58M | 0.08% | 308 |
|
|
2021
Q3 | $85.9M | Buy |
929,208
+56,916
| +7% | +$4.38M | 0.09% | 272 |
|
|
2021
Q2 | $67.8M | Sell |
872,292
-13,579
| -2% | -$1.03M | 0.07% | 367 |
|
|
2021
Q1 | $66M | Buy |
885,871
+349,454
| +65% | +$32.2M | 0.08% | 348 |
|
|
2020
Q4 | $91.5M | Sell |
536,417
-50,749
| -9% | -$7.52M | 0.12% | 208 |
|
|
2020
Q3 | $82.5M | Sell |
587,166
-81,870
| -12% | -$12.4M | 0.13% | 185 |
|
|
2020
Q2 | $107M | Buy |
669,036
+138,658
| +26% | +$18.9M | 0.19% | 127 |
|
|
2020
Q1 | $51.9M | Sell |
530,378
-68,590
| -11% | -$7.84M | 0.12% | 249 |
|
|
2019
Q4 | $77.3M | Sell |
598,968
-70,352
| -11% | -$7.1M | 0.13% | 192 |
|
|
2019
Q3 | $50.4M | Sell |
669,320
-204,541
| -23% | -$24.2M | 0.09% | 294 |
|
|
2019
Q2 | $133M | Buy |
873,861
+775,458
| +788% | +$94.2M | 0.25% | 69 |
|
|
2019
Q1 | $11.7M | Sell |
98,403
-277,202
| -74% | -$35.6M | 0.02% | 696 |
|
|
2018
Q4 | $41M | Buy |
375,605
+138,218
| +58% | +$17.3M | 0.1% | 261 |
|
|
2018
Q3 | $38.3M | Buy |
237,387
+173,782
| +273% | +$23.8M | 0.07% | 324 |
|
|
2018
Q2 | $8.41M | Buy |
63,605
+11,668
| +22% | +$1.1M | 0.02% | 855 |
|
|
2018
Q1 | $3.85M | Buy |
51,937
+9,067
| +21% | +$605K | 0.01% | 1104 |
|
|
2017
Q4 | $2.38M | Sell |
42,870
-14,798
| -26% | -$784K | 0.01% | 1413 |
|
|
2017
Q3 | $2.62M | Buy |
57,668
+26,574
| +85% | +$1.06M | 0.01% | 1304 |
|
|
2017
Q2 | $1.05M | Buy |
31,094
+13,316
| +75% | +$434K | ﹤0.01% | 1827 |
|
|
2017
Q1 | $526K | Sell |
17,778
-10,673
| -38% | -$330K | ﹤0.01% | 2067 |
|
|
2016
Q4 | $780K | Buy |
+28,451
| New | +$1.14M | ﹤0.01% | 1948 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
First Trust Advisors's SRPT Position: Q1 2026 in Review
First Trust Advisors increased its Sarepta Therapeutics (SRPT) stake by 108% in Q1 2026, buying an estimated $41.5M and bringing the position to 4,135,788 shares worth $90M. The position accounts for 0.06% of the portfolio, ranked #376.
First Trust Advisors first reported a position in SRPT in Q4 2016 and has held it in 37 quarters since. The position peaked at $133M in Q2 2019. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- First Trust Advisors held 4,135,788 shares of Sarepta Therapeutics worth $90M as of Q1 2026.
- First Trust Advisors bought 2,143,211 Sarepta Therapeutics shares in Q1 2026, an estimated $41.5M.
- Sarepta Therapeutics made up 0.06% of First Trust Advisors's portfolio in Q1 2026, its #376 holding.
- First Trust Advisors first reported a position in Sarepta Therapeutics in Q4 2016 and has held it in 37 quarters since.
- First Trust Advisors's Sarepta Therapeutics position peaked at $133M in Q2 2019.
- 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.